ORLANDO, Fla.--(BUSINESS WIRE)--Hesperos, Inc., a privately held company pioneering the development of human multi-organ model systems, announced today it has been selected to showcase its technology at the 2019 BIO International Convention. The conference will take place June 3-6, 2019 at the Philadelphia Convention Center.
Hesperos’s novel “human-on-a-chip” technology, which is being developed to enable drug candidates for regulatory submission, faster and at less cost, under a $4 million Phase IIb Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS), will be featured at the convention’s Innovation Zone, a turn-key exhibit space dedicated to showcasing select NIH SBIR/STTR awardees.
“We are delighted that our technology has been selected by the NIH to be showcased at BIO,” said Hesperos Chief Scientist James J. Hickman, Ph.D. “Over the last three years, we have proven that our systems work, and we have formed multiple collaborations with companies seeking to access the next generation of preclinical drug discovery systems. We are excited to discuss updates to our platform’s capabilities and its applications for ALS, Alzheimer’s, cancer, diabetes and rare diseases with other potential partners and customers.”
Details are as follows:
Exhibit at NIH Innovation Zone
Dates:
June 4-6, 2019
Location: Booth 4270, Kiosk IZ-32
Company Presentation
Date: June 5, 2019
Time: 11 am
Location:
BIO Business Forum, Theater 4
The upcoming 2019 BIO International Convention (June 3-6 in Philadelphia, PA) features more than 16,000 attendees in the life science and application areas, including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy. The event offers opportunities to partner, learn, and network with global biotech and pharma leaders.
Hesperos first received an SBIR grant in 2016. The 18-month, $2 million Direct-to-Phase II SBIR grant was awarded to support the development of advanced manufacturing techniques of its innovative human-on-a-chip system, which is being jointly developed by the University of Central Florida and Cornell University. Hesperos was the first company to reach the Phase IIb level of funding, which is awarded to proven systems that require additional effort to enable commercial acceptance and regulatory approval.
About Hesperos:
Hesperos, Inc, is a leader in efforts to characterize an individual’s biology with human-on-a-chip microfluidic systems. Founders Michael L. Shuler and James J. Hickman have been at the forefront of every major scientific discovery in this realm, from individual organ-on-a-chip constructs to fully functional, interconnected multi-organ systems. With a mission to revolutionize toxicology testing as well as efficacy evaluation for drug discovery, the company has created pumpless platforms with serum-free cellular mediums that allow multi-organ system communication and integrated computational PKPD modeling of live physiological responses utilizing functional readouts from neurons, cardiac, muscle, barrier tissues and neuromuscular junctions as well as responses from liver, pancreas and barrier tissues. Created from human stem cells, the fully human systems are the first in vitro solutions that accurately utilize in vitro systems to predict in vivo functions without the use of animal models, as featured in Science. More information is available at http://www.hesperosinc.com
